Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.

Also called NCT02556918

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02556918
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02556918. Randomized; single masking; primary purpose prevention. Start 2016-01 (registry gives no type); primary completion 2018-11-06 (actual). Results posted on 2019-12-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
Acronym
SITA-CABGDM
Condition
Hyperglycemia
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo
Intervention (Drug)
Regular Human Insulin
Intervention (Drug)
Insulin glargine
Intervention (Drug)
Supplemental insulin (Insulin lispro)
Intervention (Drug)
Supplemental insulin (Insulin aspart)
Lead sponsor
Emory University (class: other)

Record details

Record id
cardio:ct-nct02556918
Content hash
30c5c144179f1968dfcac1991fb3591a46b2d021d458c333357287dc80f5b369